Aura Biosciences (AURA) Total Current Liabilities (2020 - 2026)

Aura Biosciences has reported Total Current Liabilities for 7 years, with the latest figure at $16.7 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 37.35% year-over-year to $16.7 million; the trailing twelve-month figure through Mar 2026 stood at $16.7 million (up 37.35% YoY), and the FY2025 full-year result was $18.4 million, up 23.27% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $16.7 million, down from $18.4 million in the prior quarter.
• The five-year high for Total Current Liabilities was $18.8 million in Q3 2025, with the low at $5.0 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $11.9 million across 5 years, with a median of $10.9 million in 2023.
• Annual changes were most pronounced in 2022 — Total Current Liabilities soared 70.88% — and 2023, when it rose 9.33%.
• Aura Biosciences' Total Current Liabilities stood at $10.5 million in 2022, then rose by 18.17% to $12.4 million in 2023, then gained by 20.68% to $14.9 million in 2024, then climbed by 23.27% to $18.4 million in 2025, then declined by 9.12% to $16.7 million in 2026.
• The last three Total Current Liabilities figures came in at $16.7 million (Q1 2026), $18.4 million (Q4 2025), and $18.8 million (Q3 2025), per Business Quant data.